Archive: 2024 CML Publications

2024 Clinical Papers

December

Warm autoimmune hemolytic anemia as first presentation of chronic myeloid leukemia: A Case Report
Tawalbeh A et al. Case Rep Oncol, December 2024
open access publication

Chronic myeloid leukemia treatment (PDQ): Health Professional Version. Review
PDQ Adult Treatment Editorial Board, December 2024

An important oversight in the World Health Organization diagnostic classification: Chronic myeloid leukemia with the PML::RARA fusion clone
Wang J et al. Haematologica, December 2024
open access publication

Successful pregnancy and delivery after frozen-thawed embryo transfer following a third discontinuation of tyrosine kinase inhibitors in a women with chronic myeloid leukemia
Takayama K et al. Int Med, December 2024
open access publication

Asciminib in newly diagnosed chronic myeloid leukemia. Reply.
Hochhaus A et al. N Engl J Med, December 2024

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Hughes TP et al. J Hematol Oncol, December 2024
open access publication

The effect of body mass index on the safety of bosutinib in patients with chronic myeloid leukemia: A post hoc pooled data analysis
Isfort S et al. Leuk Res, December 2024

Advanced-stage chronic myeloid leukemia: Options for difficult treatment situations – Review
Atallah E and Deininger M. Drugs, December 2024

Novel treatment strategies for chronic myeloid leukemia
Cruz-Rodriguez N and Deininger M. Blood, December 2024

Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia: A Report from the RESIDIAG Study
Guerineau H et al. Am J Hematol, December 2024
open access publication

Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia
Yang Y et al. Haematologica, December 2024
open access publication

Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) - Review
Lagana A. at al. Expert Rev Hematol, December 2024

Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients
Clark SE et al. J Oncol Pharm Pract, December 2024

Is there really an accelerated phase of chronic myeloid leukemia at presentation?
Yang S et al. Leukemia, December 2024
open access publication

November

Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet International registry
Chelycheva E et al. Leukemia, November 2024
open access publication

Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis
Naka R et al. Int J Hematol, November 2024

Arterial occlusive events in a patient with chronic myeloid leukemia treated with ponatinib
Imataki O and Uemura M. Clin Case Rep, November 2024
open access publication

Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib and asciminib: A phase 1b randomized clinical trial
Jabbour E et al. JAMA Oncol, November 2024

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND Study
Yeung DT et al. Blood, November 2024

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
Guilhot F and Hehlmann R. Blood, November 2024

Dose modifications in the management of chronic phase chronic myeloid leukemia: Who, what, and when - Review
Oehler VG et al. J Natl. Compr Canc Netw, November 2024
open access publication

Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia
Chen EY et al. Eur J Haematol, November 2024
open access publication

Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia
Ishii Y et al. Int J Haematol, November 2024

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE Observational Study
Huguet F et al. Br J Haematol, November 2024
open access publication

Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
Okada Y et al. Cancer, November 2024

Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukemia patients initially treated with imatinib: An extensive, multicentred and retrospective study to develop a prognostic model
Zeng T et al. Clin Trans Med, November 2024
open access publication

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukemia and Philadelphia chromosome-positive acute myeloid leukemia: A Single arm, single centre phase 2 trial
Short NJ et al. Lancet Haematol, November 2024

October

Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal response to 3 months of imatinib therapy: final 5-year results from DASCERN
Cortes JE et al. Haematologica, Oct 2024
open access publication

Ischemic stroke as a presenting feature of promyelocytic blast phase in CML – an uncommon presentation: a case report and literature review in the post imatinib era
Tripathi S et al. Ann Hematol, Oct 2024

Nilotinib versus dasatinib in achieving MR4.5 for de novo CML: The randomized JALSG CML212 study
Matsumura I et al. Blood Adv, Oct 2024
open access publication

Tyrosine kinase inhibitor for CML: All the same?
Veltmaat L & Cortes J. Blood Adv, Oct 2024
open access publication

Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic-phase: The ASC2ESCALATE Phase II trial
Atallah E et al. Future Oncol, Oct 2024
open access publication

Viral infections and incidence of reactivations in chronic myeloid leukemia patients
Addapt MD et al. Oncology, Oct 2024

Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: A systematic review and meta-analysis
Zheng Z et al. Discov Oncol, Oct 2024
open access publication

Asciminib in advanced-line of treatment of CML
Shacham-Abdulafia A et al. Eur J Haematol, Oct 2024
open access publication

Intensification of upfront chemotherapy for patients with myeloid blast crisis in CML: A single centre experience
Lee BJ et al. Ann Hematol, Oct 2024
open access publication

Sudden blast crisis in a CML patient in treatment-free remission: A case report and literature review
Liang Q et al. Acta Haematol, Oct 2024

September

Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding – Review
Cortes JE et al. Clin Cancer Res, Sept 2024

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
Pérez-Lamas L et al. Ann Hematol, Sept 2024
open access publication

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
Eide CA et al. Cancer Cell, Sept 2024

Choice of frontline tyrosine-kinase inhibitor and early events in very elderly patients with chronic myeloid leukemia in chronic-phase: A “Campus CML” Study
Bucelli C et al. Eur J Haematol, Sept 2024
open access publication

Real-world evaluation of treatment patterns and clinical outcomes among patients with chronic myeloid leukemia in chronic-phase treated with asciminib in clinical practice in the US: Real-world asciminib treatment outcomes in CML-CP
Atallah E et al. Clin Lymphoma Myeloma Leuk, Sept 2024

Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia
Zu Y et al. J Hematol Oncol, Sept 2024
open access publication

Treatment-free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects – Review
Cattaneo D et al. Hematol Oncol, Sept 2024

Deep molecular response rate in chronic phase chronic myeloid leukemia: Eligibility to discontinuation related to time to response and different frontline TKI in the experience of the Gimema Labnet CML National Network
Breccia M et al. Clin Lymphoma Myeloma Leuk, Sept 2024

Dose justification for asciminib in patients with Philadelphia chromosome positive chronic myeloid leukemia with and without the T315I mutation
Combes PF et al. Clin Pharmacokinet, Sept 2024
open access publication

CML 25 years later – Poised for another breakthrough?
Abruzzese E. N Engl J Med, Sept 2024

Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4First trial
Srinivasan N et al. Am J Hematol, Sept 2024
open access publication

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort
Saugues S et al. Haematologica, Sept 2024
open access publication

Triplet therapy for advanced BCR::ABL1 positive myeloid leukemia
Copland M. Lancet Haematol, Sept 2024

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias
Vedula RS et al. Blood, Sept 2024

The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with imatinib
Omran MM et al. Leuk Lymphoma, Sept 2024

August

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial
Gambacorti-Passerini C et al. Leukemia, August 2024
open access publication

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: Results from the ASCEND study
Yeung DT et al. Blood, August 2024

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
Jabbour E and Kantarjian H. Am J Hematol, August 2024
open access publication

Optimal frontline therapy of chronic myeloid leukemia today, and related musings
Kantarjian HM et al. Am J Hematol, August 2024
open access publication

Ponatinib review of historical development, current status, and future research
Kantarjian HM et al. Am J Hematol, August 2024

Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan
Takahashi N et al. Jpn J Clin Oncol, August 2024
open access publication

Imatinib versus newer generation tyrosine kinase inhibitors for upfront therapy in chronic-phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?
Lipton JH et al. Am J Hematol, August 2024
open access publication

A lower initial dose of bosutinib for patients with chronic myeloid leukemia resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 (BOGI) trial
Ureshino H et al. Int J Hematol, August 2024
open access publication

Presentation of chronic myeloid leukemia in basophilic blast crisis
Hazarika B and Bain BJ Am J Hematol, August 2024
open access publication

Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of literature
Sharma D et al. Ann Diag Pathol, August 2024

Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China
Cheng F et al. Ther Adv Hematol, August 2024
open access publication

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Leyte-Vidal A. et al. Blood, August 2024

Shedding light on resistance to asciminib (Comment on Leyte-Vidal et al)
Breccia M. Blood, August 2024

Global trial representation and availability of tyrosine kinase inhibitors for treatment of chronic myeloid leukemia
Casey M et al. Cancers, August 2024
open access publication

The Mozart effect in chronic myeloid leukemia
Stentoft J et al. Br J Haematol, April 2024
open access publication

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Pérez-Lamas L et al. Ann Hematol, April 2024

Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature - Review
Sharma D et al. Ann Diagn Pathol, April 2024

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Tian J et al. J Cancer Res Clin Oncol, April 2024
open access publication

Effect of tyrosine kinase inhibitor therapy on estimated glomerular filtration rate in patients with chronic myeloid leukemia
Sönmez Ö et al. Clin Lymphoma Myeloma Leuk, April 2024

Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models
Zad Z et al. Leuk Res, April 2024

Prognostic impact of bone marrow fibrosis and effects of tyrosine kinase inhibitors on bone marrow fibrosis in chronic myeloid leukemia
Pepeler MS et al. Clin Lymphoma Myeloma Leuk, April 2024

The depth of molecular response in patients with chronic myeloid leukemia correlates with changes in humoral immunity
Janowski M et al. J Clin Med, April 2024
open access publication

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase chronic myeloid leukemia
Jain AG et al. Ann Hematol, April 2024
open access publication

March

Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Chen H et al. Oncol Ther, March 2024
open access publication

Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia
Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024

Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring
Omran MM et al. Eur J Clin Pharmacol, March 2024

Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts
Lee SJ et al. J Clin Lab Anal, March 2024
open access publication

Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation
Dimitriou M et al. Blood, March 2024
open access publication

Mutations in myeloid transcription factors and activated signalling genes predict chronic myeloid leukemia outcomes
Perusini MA et al. Blood Adv, March 2024

Clinical pharmacokinetics and drug-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia: A clinical perspective – Review
Cheng F et al. Crit Rev Oncol Hematol, March 2024

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? – Review
Kantarjian H et al. Leukemia, March 2024

Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia positive clone or variant Philadelphia translocations
Claudiani S et al. Am J Hematol, March 2024
open access publication

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Brioli A et al. Leukemia, March 2024
open access publication

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission
Mahon FX et al. J Clin Oncol, March 2024

Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
Smith BD et al. Leuk Res, March 2024

High efficacy and safety of asciminib in a chronic myeloid leukemia patient with chronic kidney disease following renal transplantation
Uchida Y et al. Intern Med, March 2024
open access publication

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Bonifacio M et al. Blood Cancer J, March 2024
open access publication

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI Stopping Trial HALF
Zácková D et al. Leukemia, March 2024
open access publication

The role of molecular or cytogenetic response as a favourable prognostic factor before hematopoietic cell transplantation for chronic myeloid leukemia
Medeiros GRO et al. Transplant Cell Ther, March 2024

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia
Haddad FG et al. Am J Hematol, March 2024
open access publication

The screening of microRNAs in chronic myeloid leukemia: A clinical evaluation
Wosniaki DK et al. Int J Mol Sci, March 2024
open access publication

A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia
Galimberti S et al. Pharmaceutics, March 2024
open access publication

The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia
Bi X et al. J Hematol, March 2024

The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia
Nieves Saez Perdomo, M et al. Hematol Rep, March 2024
open access publication

Clinical outcomes of patients with lymphoid blast phase of chronic myeloid leukemia treated with CAR T-cell therapy
Liu Y et al. Blood Cancer J, March 2024
open access publication

February

Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANS1::ARC1A) alteration: A case report with insights on the molecular landscape
Fontana D et al. Ann Hematol, February 2024

Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
Wang L et al. Int J Lab Hematol, February 2024

Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction
Mu H et al. Hematol Transfus Cell Ther, February 2024
open access publication

HIF2-alpha expression in CML patients receiving hydroxyurea prior to imatinib that achieved major molecular response (MMR) versus in those not achieving MMR
Rinaldi I et al. J Blood Med, February 2024
open access publication

Chronic myeloid leukemia 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah NP et al. J Natl Comp Canc Netw, February 2024
open access publication

Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis: A Report from the BCR::ABL1 Pathology Group
Rivera D et al. Mod Pathol, February 2024
open access publication

Chronic myeloid leukemia diagnosed in pregnancy: management and outcomes of 87 patients reported to the European LeukemiaNet International Registry
Chelysheva E et al. Leukemia, February 2024

Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
Benesova A et al. Am J Hematol, February 2024
open access publication

The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: Is it the same in all settings?
Elmakaty I et al. Cancers(Basel), February 2024
open access publication

Maximising the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches
Lipton JH. Clin Drug Investig, February 2024

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myeloid leukemia patients
Alcazar V et al. Br J Haematol, February 2024
open access publication

Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: Strategies to optimize success and new directions – Review
Réa D et al. Curr Hematol Malig Rep, February 2024

Male fertility and fatherhood in chronic myeloid leukemia: Current understanding and future perspectives - Review
Elsabagh AA et al. Cancers(Basel), February 2024
open access publication

Stem cell allografting for chronic myeloid leukemia in the tyrosine kinase era: Forgotten but not gone - Review
Tang K & Lipton LH. Leuk Lymphoma, February 2024

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Hornak T et al. Am J Hematol, February 2024
open access publication

Navigating the management of chronic phase chronic myeloid leukemia in the era of generic BCR::ABL1 tyrosine kinase inhibitors - Review
Haddad FG & Kantarjian H. J Natl Compr Canc Netw, February 2024
open access publication

January

Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A Case report and literature review
Li Y et al. Medicine (Baltimore), January 2024
open access publication

Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: A Comparative study from the Chronic Malignancies Working Party of the EBMT (CHWP-EBMT)
Ortí G et al. Transplant Cell Ther, January 2024
open access publication

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Velmaat L and Cortes J. Blood, January 2024

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Jabbour E et al. Leukemia, January 2024
open access publication

Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches
Lipton JH. Clin Drug Investig, January 2024

How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to J.P Gale and J. Chen
Pfirrmann M et al. Leukemia, January 2024
open access publication

Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with Dasatinib – Interim results from the DAstop2 trial
Flygt H et al. Leukemia, January 2024
open access publication

Safety and efficacy of asciminib in a chronic myloid leukemia patient with chronic kidney disease: A case report
Alshurufa A et al. Case Rep Oncol, January 2024
open access publication

A review of the therapeutic role of bosutinib in chronic myeloid leukemia – Review
Kantarjian HM et al. Clin Lymphoma Myeloma Leuk, January 2024

Safety and efficacy of tyrosine kinase inhibitors in very elderly patients (≥ 75 years) with chronic myeloid leukemia
Costa A et al. J Clin Med, January 2024
open access publication

Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
Dereme J et al. Ann Hematol, January 2024

What do atomic bomb survivors teach us about treatment-free remission in people with chronic myeloid leukemia
Radivoyevitch T et al. Leukemia, January 2024
open access publication

How to individualized therapy after failing milestones in chronic myeloid leukemia: weighting late response and early death from CML against risk of alternative therapy
Hehlmann R and Lauseker M. Leukemia, January 2024
open access publication

Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL fusion gene in Ph-positive leukemias
Sponseiler I et al. Am J Hematol, January 2024
open access publication

Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Chen H et al. Oncol Ther, March 2024
open access publication

Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia
Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024

Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring
Omran MM et al. Eur J Clin Pharmacol, March 2024

Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts
Lee SJ et al. J Clin Lab Anal, March 2024
open access publication

Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation
Dimitriou M et al. Blood, March 2024
open access publication

2024 Scientific Papers

December

Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis
Jiang Y et al. Hematology, December 2024
open access publication

Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T3I5I BCR::ABL-1 mutation
Quezada Meza CP et al. Int J Biol Macromol, December 2024
open access publication

Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells
Kawashima K et al. Biomed Pharmacother, December 2024
open access publication

Targeting the insulin-like growth factor-1 to overcome imatinib resistance in chronic myeloid leukemia
Okabe S et al. Discov Mol, December 2024
open access publication

Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells
Polamski M et al. Eur J Med Chem, December 2024
open access publication

Synergistic effects of inecalcitol with imatinib and dasatinib on chronic myeloid leukemia cell lines
Angel S et al. Anticancer Res, December 2024
open access publication

Bortezomib induces cell apoptosis and increases the efficacy of alpha PD-1 in BCR:::ABL T3I5I mutation CML by targeting UBE2Q1
Jiang F et al. Int Immunopharmacol, December 2024

Quantitative detection of T3151 mutations of BCR::ABL1 using digital droplet polymerase chain reaction
Mu H et al. Hematol Transfus Cell Ther, December 2024
open access publication

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myeloid leukemia after tyrosine kinase inhibitor treatment
Guo YG et al. Hematology, December 2024
open access publication

BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia
Suzuki K et al. Cancer Si, December 2024
open access publication

November

Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia
Afzal A et al. BMC Cancer, November 2024
open access publication

Targeting DDX3X eliminates leukemia stem cells in chronic myeloid leukemia by blocking NT5DC2 mRNA translation
Duan C et al. Oncogene, November 2024

Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia
Kuznetsova V et al. Blood Adv, November 2024

Investigation of TSRP reverse imatinib resistance through the PI3K/Akt pathway in chronic myeloid leukemia
He Y et al. Ann Hematol, November 2024

Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 on imatinib
Karami N et al. Nol Biol Rep, November 2024

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
Warfvinge R et al. eLife, November 2024
open access publication

Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia
Toloza MY et al. Ann Hematol, November 2024

A novel next generation sequencing assay for the identification of BCR::ABL1 transcript type and accurate and sensitive detection of TKI-resistant mutations
Yan Z et al. J Appl Lab Med, November 2024

The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy
Decroos A. et al. Front Immunol, November 2024
open access publication

October

Phenotypically plastic drug-resistant CML cell line displays enhanced cellular dynamics in a zebrafish xenograft model
Baykal S et al. J Cell Mol Med, Oct 2024
open access publication

Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia
Luo Z et al. Cancer Res, Oct 2024

Computationally driven discovery of a BCR::ABL1 kinase inhibitor with activity in multi-drug resistant CML
Hill J et al. J Med Chem, Oct 2024
open access publication

The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies
Yu M et al. Leukemia, Oct 2024

September

Effects of imidazole derivates on cellular proliferation and apoptosis in myeloid leukemia
Nadeem BB et al. BMC Cancer, Sept 2024
open access publication

Association of PARP1 expression levels and clinical parameters in different leukemic subtypes with BCR::ABL1 p190+ translocation
DE Morais GP et al. Cancer Diagn Progn, Sept 2024
open access publication

Strategies to overcome splicing variants interference in mutational testing for BCR::ABL1 KD
Bulchi J et al. Leuk Res, Sept 2024

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL isoforms are resistant to asciminib
Leske IB and Hantschel O. Leukemia, Sept 2024
open access publication

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Innes AJ et al. Leukemia, Sept 2024
open access publication

Absence of ABL1 exon 2-decoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
Leyte-Vidal A et al. Leukemia, Sept 2024
open access publication

Has_cir_0006010 and has_circ_0002903 in peripheral blood serve as novel diagnostic, surveillance and prognostic biomarkers for disease progression in chronic myeloid leukemia
Zhao J et al. BMC Cancer, Sept 2024
open access publication

PBA2, a novel inhibitor of the beta-catenin//CBP pathway eradicates chronic myeloid leukemia including BCR-ABL T315I mutation
Yang K et al. Mol Cancer, Sept 2024
open access publication

Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report
Ahmad F et al. Ann Hematol, Sept 2024

In silico molecular modelling of four new afatinib derived molecules targeting the inhibition of the mutated form of BCR-ABL T315I
Rocha KML et al. Molecules, Sept 2024
open access publication

August

Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia: as an immunogenic anticancer strategy
Schnekenburger M et al. Cancer Commun (Lond), August 2024
open access publication

Imatinib therapy significantly reduces carnitine cell intake, resulting in adverse events
Burda P et al. Mol Metabol, August 2024
open access publication

Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia
Su R et al. Cell Death Dis, August 2024
open access publication

Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
Komic H et al. Haematologica, August 2024
open access publication

Raddeanin A augments the cytotoxicity of natural killer cells against chronic myeloid leukemia cells by modulating MAPK and Ras/Raf signalling pathways
Hsiek MJ et al. J Cell Mol Med, August 2024
open access publication

BCR::ABL1 proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of PH+ leukemias?
Cruz-Rodriguez N et al. Leukemia, August 2024
open access publication

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Fontana D et al. Leukemia, August 2024
open access publication

July

miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia
Poggio P et al. Sci Rep, July 2024
open access publication

Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK
Huang CY et al. Commun Biol, July 2024
open access publication

BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia
Schmidlechner L et al. Oncol Lett, July 2024
open access publication

Immunophenotypic features of early haematopoietic and leukemia stem cell - Review
Reuvekamp T et al. Int J Lab Hematol, July 2024
open access publication

Distinct pattern of genomic breakpoints in CML and BCR::ABL1 positive ALL: Analysis of 971 patients
Hovorkova L Mol Cancer, July 2024
open access publication

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells
Nemethova N et al. Am J Physiol Cell Physiol, July 2024
open access publication

Blockade of PD-1 and TIM-3 ameliorates CD8+ T cell exhaustion in a mouse model of CML
Jin T et al. Cell Biochem Biophys, July 2024

Enhanced antitumor activity by the combination of Dasatinib and Selinexor in chronic myeloid leukemia
Spampinato M et al. Pharmaceuticals (Basel), July 2024
open access publication

Overcoming flumatinib resistance in chronic myeloid leukemia: Insights into cellular mechanisms and ivermectin’s therapeutic potential
Huang J et al. J Cell Mol Med, July 2024
open access publication

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Zibrova D et al. Mol Cell Biochem, July 2024
open access publication

The therapeutic and biomarker significance of ferroptosis in chronic myeloid leukemia
Zhong F et al. Front Immunol, July 2024
open access publication

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
Eadie LN et al. Blood, June 2024

June

Alterations in pharmacogenetic genes and their implications for imatinib resistance in chronic myeloid leukemia patients from an admixed population
Cereja-Pantoja KBC et al. Cancer Chemother Pharmacol, June 2024

Constitutional DNA polymorphisms associated with the plasma imatinib concentration in chronic myeloid leukemia patients
Bruzzoni-Giovanelli H et al. Pharmaceutics, June 2024
open access publication

Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia
Khalaf A et al. Sci Transl Med, June 2024

HIF-2alpha inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment
Wang J et al. Cancer Lett, June 2024

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
Minhajuddin M et al. Haematologica, June 2024

RNA binding protein Lin28B promotes chronic myeloid leukemia blast crisis by transcriptionally upregulating miR-181d
Zhou M et al. Mol Cancer Res, June 2024

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to ascinimib
Leske IB & Hantschel O. Leukemia, June 2024
open access publication

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
Chatain N et al. Leukemia, June 2024
open access publication

May

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Perusini MA et al. Blood Adv, May 2024
open access publication

Platelet microparticles influence gene expression and modulate biological activities of chronic myeloid leukemia cells (K562)
Nikravesh F et al. Mol Biol Rep, May 2024

Integrated functional genomic screening to bypass tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Beinortas T and Huntly BJP. Cell Rep Med, May 2024
open access publication

Outcome of 3q26.2/MECOM rearrangement in chronic myeloid leukemia
Akiyama H et al. Int J Hematol, May 2024

Peripheral blood quantification of CD26 positive leukemic stem cells as a predictor to tyrosine kinase inhibitor response in chronic myeloid leukemia
Chaudhary N et al. Int J Lab Hematol, May 2024

TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia
Morii M et al. Leukemia, May 2024

April

Oxidative stress and chronic myeloid leukemia: A Balance between ROS-mediated Pro- and Anti-apoptotic effects of tyrosine kinase inhibitors - Review
Allegra A et al. Antioxidants(Basel), April 2024
open access publication

Ponatinib and STAT5 inhibitor pimozide combined synergistic treatment applications potentially overcome drug resistance via regulating the cytokine expressional network in chronic myeloid leukemia cells
Tezcanli Kaymaz B et al. J Interferon Cytokine Res, April 2024

Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line
Demirkiran N et al. Med Oncol, April 2024

Influence of genetic polyphormisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia
Cheng F et al. Int Immunopharmacol, April 2024

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Leyte-Vidal A et al. Blood, April 2024

Unveiling IL6R and MYC as targeting biomarkers in imatinib-resistant CML through advanced non-invasive Apoptosis Detection Sensor Version 2 Detection
Lee CH et al. Cells, April 2024
open access publication

Characterization of asciminib-resistant Philadelphia chromosome-positive cells
Okabe S et al. World J Oncol, April 2024
open access publication

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
Adnan-Awad S et al. Cell Rep Med, April 2024
open access publication

High level of CD8+ PD-1+ cells in patients with chronic myeloid leukemia who experienced loss of MMR after imatinib discontinuation
Kwasnik P et al. Cells, April 2024
open access publication

March

The potential of circHIPK3 as a biomarker in chronic myeloid leukemia – Review
Gomez EW et al. Front Oncol, March 2024
open access publication

CFL1 is implicated in chronic myeloid leukemia response during imatinib therapy
Yin X et al. J Cancer, March 2024
open access publication

February

Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
Jiang L et al. Genomics, February 2024
open access publication

Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models
Ansari AS et al. J Control Release, February 2024

AS1041, a novel derivative of marine natural compound Aspergiolide A induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation
Lu X et al. Biomed Pharmacother, February 2024
open access publication

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
Klaihmon P et al. Sci Rep, February 2024

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia - Review
El-Tanani M et al. Pathol Res Pract, February 2024
open access publication

Beyond BCR::ABL1 – The role of genomic analysis in the management of CML
Branford S et al. J Natl Comp Canc Netw, February 2024
open access publication

Leukemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche
Dawson A et al. Nat Commun, February 2024
open access publication

Integrated stress response potentiates ponatinib-induced cardiotoxicity
Yan G et al. Circ Res, February 2024

Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: A Meta analysis
Romero-Morales P et al. Genes(Basel), February 2024
open access publication

Expression of genes potentially involved in loss of response in patients with chronic myeloid leukemia
Benegas P et al. Gene, February 2024

State-transition modelling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
Frankhauser DE et al. Leukemia, February 2024
open access publication

January

Circ-SIRT1 upregulated ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3
Zhang R et al. Gene, January 2024

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
Sun J et al. Int J Biol Sci, January 2024
open access publication

Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels
Bansal M et al. Med Oncol, January 2024

Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules - Review
Bernardi S et al. Front Oncol, January 2024
open access publication

Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation
Boucher L et al. Leuk Res, January 2024

Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia
Zhong F et al. Front Oncol, January 2024
open access publication

Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSC) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Benjamin ESB Cell Signal, January 2024

Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia
Lettnin AP et al. Gene, January 2024

Activating p53 abolishes self-renewal of quiescent leukemic stem cells in residual CML disease
Scott MT et al. Nat Commun, January 2024
open access publication

Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
Imeri J et al. Front Immunol, January 2024
open access publication

2024 Low- and Middle-Income Countries Publications

Worldwide Publications of Interest

Bringing global hematology research to the forefront
Gómez-De León A et al. Blood Adv, July 2024

CML Publications from Africa

Early molecular response to imatinib first-line therapy and predictive factors of poor outcomes for chronic myeloid leukemia patients in Cote d’Ivoire
Koffi KG et al. Adv Hematol, December 2024
open access publication

Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia
Mongoura SA et al. Cancer Chemother Pharmacol, December 2024
open access publication

Health-related quality of life and financial burden in Ethiopian patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors:A cross sectional study
Tadesse F et al. JCO Global Oncol, November 2024
open access publication

Correlation of T regulatory cells, cytotoxic T-lymphocyte-associated antigen 4, and transforming growth-factor-beta1 with treatment response in patients with CML receiving dasatinib therapy
Singh A et al. Ann Afr Med, Oct 2024
open access publication

Late presentation of chronic myeloid leukemia patients in a low-income country: The prognostic implications and impact on treatment outcome
Nelson EA et al. BMC Res Notes, Sept 2024
open access publication

Novel ABL1 mutation in a Moroccan CML patient with imatinib resistance
El Bouchikhi I et al. Cancer Genet, Sept 2024
open access publication

Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa
Ayalew ZS et al. EJHaem, July 2024, eCollection Aug 2024
open access publication

Prognostic role of human leukocyte antigen alleles and cytokine single-nucleotide polymorphisms in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor drugs
Birru SK et al. Genes(Basel), June 2024
open access publication

Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation of a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study
Urgessa F et al. BMC Cancer, April 2024
open access publication

Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco
Benchikh S et al. Ann Hematol, April 2024

CML Publications from the Middle East

Dilemma in diagnosis and management of CML in Pakistan
Khan S et al. Turk J Hematol, Oct 2024
open access publication

Anti-leukemic effects of small moleculre inhibitor of c-Myc (10058-F4) in chronic myeloid leukemia cells
Zehtabcheh S et al. Asian Pac J Cancer Prev, June 2024
open access publication

Nilotinib-associated multiple silent arterial stenosis in a patient with chronic myeloid leukemia
Tokatli M et al. Turk J Haematol, March 2024
open access publication

Pharmacokinetics of imatinib mesylate and development of limited sampling strategies for estimating the area under the concentration-time curve of imatinib mesylate in Palestinian patients with chronic myeloid leukemia
Adawi DH et al. Eur J Drug Metab Pharmacokinet, January 2024

CML Publications from Asia

Impact of dasatinib on female reproductive health in Philadelphia-positive leukemia patients
Kintada S et al. Indian J Hematol Blood Transf, December 2024

Occurrence of existing BCR-ABL baseline mutations and associated haplotype (NmR) among chronic myeloid leukemia patients with diverse imatinib response: A hospital-based study from North-East India
Hazarika G et al. Biochem Genet, December 2024

Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib
Saj F et al. Indian J Hematol Blood Transfus. October 2024

Maternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact
Bhattacharjee U et al. Indian J Hematol Blood Transfus., October 2024

Imatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case-control Study.
Shakar G et al. Indian J Hematol Blood Transfus., October 2024

Extramedullary T-lymphoblastic blast crisis in a young male with chronic myeloid leukemia: A rare presentation diagnosed on cytology and flow cytometric immunophenotyping
Kaur G et al. Diagn Cytopathol. November 2024

Tyrosine kinase inhibitor-induced intracranial artery stenosis – A rare cause of TIA in a patient with CML
Agrawal SS et al. Ann Indian Acad Neurol, Oct 2024
open access publication

Evaluation of bone turnover markers in patients with acute and chronic leukemia
Al Qaisi RA et al. Indian J Clin Biochem, July 2024

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance: a Malaysian Cohort Study
Seman ZA et al. BMC Res Notes, April 2024
open access publication

Occurrence of existing BCR-ABL baseline mutations and associated haplotype (NmR) among chronic myeloid leukemia patients with diverse imatinib response: A Hospital-based study from North-East India
Hazarika G et al. Biochem Genet, February 2024

CML Publications from Latin America

Expression of HOTAIR and PTG2 as potential biomarkers in chronic myeloid leukemia patients in Brazil
Kubaski Benevides AD et al. Front Oncol, Oct 2024
open access publication

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia
Barranco G et al. Cancer Causes Control, Sept 2024

Association between plasma imatinib levels and response to treatment of chronic myeloid leukemia in patients from Manaus, Brazil
Henriques MA et al. J Oncol Pharm Pract, May 2024

2024 COVID-19 and CML Publications

Papers on COVID-19 and CML

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
El-Ashwah S et al. Leuk Lymphoma, January 2024
open access publication

Papers on COVID-19 vaccines and CML

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: Insights from real-world in Brazil and the US
Toreli ACM et al. Leuk Lymphoma, July 2024
open access publication

2024 Pediatric CML Publications

Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort
Roy Moulik N et al. Am J Hematol, Nov. 2024
open access publication

Clinical characteristics and outcomes of CML in adolescents and young adults
Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024

A high proportion of germline variants in pediatric chronic myeloid leukemia
Krumbold M et al. Mol Cancer, Sept 2024
open access publication

CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast crisis
Kramp LJ et al. Ann Hematol, Sept 2024
open access publication

Low-level BCR::ABL1 transcript at diagnosis in childhood leukemia: A 10-year single institution study
Cain LE et al. Genes Chromosomes Cancer, Sept 2024

Chronic myeloid leukemia in adolescents and young adults: Clinicopathological variables and outcomes
Abdulla MA et al. Oncology, July 2024
open access publication

Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review
Katsarou D et al., Curr Pharm Des, July 2024

Childhood chronic myeloid leukemia treatment (PDQ)
PDQ Pediatric Treatment Editorial Board June, 2024
In: PDQ Cancer Information Summaries (Internet) Bethesada (MD) National Cancer Institute (US); 2002-
open access publication

Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with CML: A prospective multicentre trial of the I-BFM Study Group
Pichler H et al. Br J Haematol, May 2024
open access publication

Priapism and chronic myeloid leukemia in an adolescent. Rare debut presentation. A case report
Romero-Guerra AL et al. Arch Argent Pediatr, April 2024
open access publication

Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Behrens YL et al. Haematologica, March 2024
open access publication

Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
Stiehler S et al. Haematologica, March 2024
open access publication

Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patient with chronic myeloid leukemia
Abdallah AM et al. Leuk Lymphoma, March 2024

Chronic spontaneous urticarial as the presenting factor in a paediatric case of chronic myeloid leukemia
Sutton KM et al. Pediatr Blood Cancer, March 2024

Bosutinib in resistant and intolerant pediatric patients with chronic phase CML: Results from the Phase I part study ITCC054/COG AMML1921
Brivio E et al. J Clin Oncol, March 2024
open access publication

A 3-year old with chronic myeloid leukemia
Coty-Fatall Z & Richardson A. Blood, February 2024

Challenges in management of pediatric chronic myleloid leukemia (pCML) in the low- and middle income countries (LMICs): Insights from an Interntional CML Foundation (iCMLf) Multi National Study
Roy Moulik N et al. Pediatr Hematol Oncol, Jan 2024

Pediatric chronic myeloid leukemia P190 variant with IgA vasculitis: Rare association - case report
Shah K et al. Pediatr Blood Cancer, Jan 2024